Predictive value of serum NT-proBNP concentrations for assessment hemodynamically significant patent ductus arteriosus in very preterm infants
DOI:
https://doi.org/10.15574/SP.2021.113.28Keywords:
hemodynamically significant patent ductus arteriosus, PDA, NT-proBNP, prognostic value, very preterm infantsAbstract
Hemodynamically significant patent ductus arteriosus (PDA) is a common complication in very preterm infants born at less than 32 weeks of gestation. At the same time, currently, there are no uniform criteria to identify the actual hemodynamic significance of PDA and generally accepted management approaches to such infants.
Purpose — to assess the predictive value of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels for hemodynamically significant PDA in very preterm infants.
Materials and methods. Fifty-two preterm infants with gestational age <32 weeks, chronological age <72 h, and PDA diameter >1.5 mm were involved in a randomized study. Twenty-seven (52%) of them were treated with ibuprofen or paracetamol starting within the first 3 days of life. Expectant management was applied to 25 (48%) infants. All patients underwent daily echocardiographic and two serum NT-proBNP measurements within the first 10 days after birth. According to the results of echocardiographic and clinical monitoring, 2 groups of patients were formed retrospectively. In 22 (42%) of them hemodynamically significant PDA (hsPDA) was diagnosed, and 30 (58%) had hemodynamically insignificant ductus arteriosus.
Results. The percentage of infants who received pharmacological PDA treatment was not significantly different between the groups (p>0.05). Serum NT-proBNP concentrations at the median age of 2 and 8 days were significantly higher in infants with hsPDA (p<0.01). By the eighth day of life, the NT-proBNP level in both groups significantly decreased but remained considerably higher in newborns with hsPDA. Serum NT-proBNP concentrations on the second-third day of life could reliably predict hsPDA (AUC=0.93; 95% confidence interval: 0.86–1.0; p<0.05).
Conclusions. Serum NT-proBNP concentrations on the second day of life >12000 pg/ml could reliably predict hsPDA.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of these Institutes. The informed consent of the patient was obtained for conducting the studies.
No conflict of interest was declared by the authors.
References
Arlettaz R. Echocardiographic Evaluation of Patent Ductus Arteriosus in Preterm Infants. (2017). Front Pediatr. 5: 147. https://doi.org/10.3389/fped.2017.00147; PMid:28680875 PMCid:PMC5478876
Bar Oz B, Lev Sagie A, Arad I, Salpeter L, Nir A. (2005). N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. Clin Chem. 51 (5): 926-927. https://doi.org/10.1373/clinchem.2005.048892; PMid:15855678
Benitz WE, Committee on Fetus and Newborn Patent Ductus Arteriosus in Preterm Infants. (2016). Pediatrics. 137 (1): e20153730. https://doi.org/10.1542/peds.2015-3730; PMid:26672023
Benitz WE. (2010). Treatment of persistent patent ductus arteriosus in pre-term infants: time to accept the null hypothesis? J Perinatol. 30 (4): 241-252. https://doi.org/10.1038/jp.2010.3; PMid:20182439
Chen S, Tacy T, Clyman R. (2010). How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol. 30 (12): 780-785. https://doi.org/10.1038/jp.2010.47; PMid:20376057
El Khuffash A, Davis PG, Walsh K, Molloy EJ. (2008). Cardiac troponin T and N-terminal-pro-B natriuretic peptide reflect myocardial function in preterm infants. J Perinatol. 28 (7): 482-486. https://doi.org/10.1038/jp.2008.21; PMid:18322550
El Khuffash A, Molloy E. (2009). The use of N-terminal-pro-BNP in preterm infants. Int J Pediatr: 175216. https://doi.org/10.1155/2009/175216; PMid:20069108 PMCid:PMC2804037
El Khuffash AF, Amoruso M, Culliton M, Molloy EJ. (2007). N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study. Arch Dis Child Fetal Neonatal Ed. 92 (5): F421-422. https://doi.org/10.1136/adc.2007.119701; PMid:17712194 PMCid:PMC2675377
Farooquia MA, Elsayeda Y, Jeyaraman MM, Dingwalld O, Tagina M et al. (2019). Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: A systematic review and meta-analysis. J Neonatal Perinatal Med. 12 (1): 1-7. https://doi.org/10.3233/NPM-17130; PMid:30040749
Fried I, Bar Oz B, Algur N, Fried E, Gavri S et al. (2006). Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics. 118 (4): e1165-1168. https://doi.org/10.1542/peds.2006-0569; PMid:16966393
Harkin P, Marttila R, Pokka T, Saarela T, Hallman M. (2018). Morbidities associated with patent ductus arteriosus in preterm infants. Nationwide cohort study. J Matern Fetal Neonatal Med. 31 (19): 2576-2583. https://doi.org/10.1080/14767058.2017.1347921; PMid:28651469
Hundscheid T, Onland W, van Overmeire B, Dijk P, van Kaam AHLC et al. (2018). Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus Trial). BMC Pediatr. 18 (1): 262. https://doi.org/10.1186/s12887-018-1215-7; PMid:30077184 PMCid:PMC6090763
Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. (2015). Diagnosing significant PDA using natriuretic peptides in pre-term neonates: a systematic review. Pediatrics. 135 (2): e510-525. https://doi.org/10.1542/peds.2014-1995; PMid:25601976
Lechner E, Wiesinger Eidenberger G, Wagner O, Weissensteiner M, Schreier Lechner E et al. (2009). Amino terminal pro B-type natriuretic peptide levels are elevated in the cord blood of neonates with congenital heart defect. Pediatr Res. 66 (4): 466-469. https://doi.org/10.1203/PDR.0b013e3181b3aee4; PMid:19581836
Letshwiti JB, Sirc J, O'Kelly R, Miletin J. (2011). Serial N-Terminal Pro-Brain Natriuretic Peptide Measurement as a Predictor of Clinically Significant Ductus Arteriosus in Preterm Infants beyond the First Week of Life. E-PAS2011.3832.313. https://doi.org/10.1038/pr.2011.892
Letzner J, Berger F, Schwabe S, Benzing J, Morgenthaler NG et al. (2012). Plasma C-Terminal Pro-Endothelin-1 and the Natriuretic Pro-Peptides NT-proBNP and MR-proANP in Very Preterm Infants with Patent Ductus Arteriosus. Neonatology. 101 (2): 116-124. https://doi.org/10.1159/000330411; PMid:21952518
Levin ER, Gardner DG, Samson WK. (1998). Natriuretic peptides. N Engl J Med. 339 (5): 321-328. https://doi.org/10.1056/NEJM199807303390507; PMid:9682046
Mannarino S, Garofoli F, Mongini E, Cerbo RM, Codazzi AC et al. (2010). BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants. Early Hum Dev. 86 (5): 295-298. https://doi.org/10.1016/j.earlhumdev.2010.04.003; PMid:20488634
Mir TS, Laux R, Hellwege HH, Liedke B, Heinze C et al. (2003). Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics. 112 (4): 869-896. https://doi.org/10.1542/peds.112.4.896; PMid:14523183
Nuntnarumit P, Khositseth A, Thanomsingh P. (2009). N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol. 29 (2): 137-142. https://doi.org/10.1038/jp.2008.185; PMid:19020527
Ramakrishnan S, Heung YM, Round J, Morris TP, Collinson P, Williams AF. (2009). Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Acta Paediatr. 98 (8): 1254-1259. https://doi.org/10.1111/j.1651-2227.2009.01315.x; PMid:19432837
Rauh M, Koch A. (2003). Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem. 49 (9): 1563-1564. https://doi.org/10.1373/49.9.1563; PMid:12928255
Richardson DK, Corcoran JD, Escobar GJ, Lee SK. (2001). SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risks cores. J Pediatr. 138 (1): 92-100. https://doi.org/10.1067/mpd.2001.109608; PMid:11148519
Sasi A, Deorari A. (2011). Patent ductus arteriosus in preterm infants. Indian Pediatr. 48 (4): 301-308. https://doi.org/10.1007/s13312-011-0062-5; PMid:21532100
Shah PS. (2019). Pharmacologic management of patent ductus arteriosus in the very preterm neonate. In: Hemodynamics and cardiology: neonatology questions and controversies. Third edition. Philadelphia, PA: Elsevier, Inc: 411-425. https://doi.org/10.1016/B978-0-323-53366-9.00023-5
Shepherd JL, Noori S. (2019). What is a hemodynamically significant PDA in preterm infants? Congenit Heart Dis. 14 (1): 21-26. https://doi.org/10.1111/chd.12727; PMid:30548469
Smith A, El Khuffash A. (2020). Defining «Haemodynamic Significance» of the Patent Ductus Arteriosus: Do We Have All the Answers? Neonatology: 1-8. https://doi.org/10.1159/000506988; PMid:32450558
Stoupakis G, Klapholz M. (2003). Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart Dis. 5 (3): 215-223. https://doi.org/10.1097/01.HDX.0000074517.30102.64; PMid:12783635
Vanderheyden M, Bartunek J, Goethals M. (2004). Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 6 (3): 261-268. https://doi.org/10.1016/j.ejheart.2004.01.004; PMid:14987574
Zonnenberg I, de Waal K. (2012). The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr. 101 (3): 247-251. https://doi.org/10.1111/j.1651-2227.2011.02468.x; PMid:21913976
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Modern Pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
